Avadel wins FDA approval for narcolepsy drug Lumryz
Lumryz is an extended-release formulation of sodium oxybate, a central nervous system (CNS) depressant. Its therapeutic effects are believed to be mediated through GABA B actions at noradrenergic and ...
Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown ...
The U.S. Food and Drug Administration has tentatively proposed a big change to food labels in the U.S., including some nutrition information on the front of packages. The new feature is designed ...
The first was a partial legal win against competitor Avadel Pharmaceuticals (AVDL) in late August, where Jazz was not able to get Avadel’s Lumryz off the narcolepsy market, but it was able to ...
Hosted on MSN7mon
Avadel surges after royalty rate awarded to Jazz in patent dispute lower than requested (update)Jazz Pharma (JAZZ) dropped 1.8%. A jury in Wilmington, Delaware ruled that Avadel's Lumryz infringes on a patent 782 for Jazz's Xyrem, court observers told Seeking Alpha on Monday. The jury ruled ...
Investopedia / Mira Norian White label products are sold by retailers with their own branding and logo but the products themselves are manufactured by a third party. White labeling occurs when the ...
(RTTNews) - Avadel Pharmaceuticals plc (AVDL), Tuesday revealed that 94 percent of patients in RESTORE study with narcolepsy preferred the once-nightly regimen of Lumryz over twice-nightly Oxybate ...
Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and were not using a stable dose of an alerting agent – – Baseline data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback